Malignant peripheral nerve sheath tumors (MPNSTs) are rare tumors for which no established systemic treatment exists. MPNSTs occur in approximately 10% of patients with neurofibromatosis type 1, with malignancy usually present in the third or fourth decade of life.1 When MPNSTs occur sporadically in the absence of neurofibromatosis, they tend to present later in life, usually in the sixth or seventh decade, and often without an inactivating alteration in neurofibromin (NF1), which is seen in patients with neurofibromatosis type 1. Wild-type NF1 protein exhibits an inhibitory effect on the RAS/RAF pathway. Such tumors exhibit increased activity in the RAS/RAF pathway by the lack of negative feedback.2 Alterations in the PI3K/PTEN/AKT pathway can also affect RAS/RAF activity3 and can be stimulated by similar stimuli as the RAS/RAF pathway.
Previously, we reported on a patient with a sporadic MPNST, whose tumor featured a BRAF V600E mutation.4 This mutation results in activation of BRAF, leading to increased activity of the RAS/RAF pathway.5 This patient had a dramatic response to vemurafenib, an inhibitor of BRAF V600E. As a result, in the current study we analyzed the presence of BRAF alterations, other RAS/RAF alterations, and other genomic alterations in all MPNSTs studied at Swedish Cancer Institute and Foundation Medicine during the past 12 years.
Drs. Ross, Ali, and Millis are employees of Foundation Medicine, Inc. Drs. Ali and Ross have equity interest in Foundation Medicine, Inc. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
This study was supported in part by the Kaplan Cancer Research Fund.
See JNCCN.org for supplemental online content.
Sun D, Tainsky MA, Haddad R. Oncogene mutation survey in MPNST cell lines enhances the dominant role of hyperactive Ras in NF 1 associated pro-survival and malignancy. Transl Oncologenomics 2012;5:1–7.
Kaplan HG. Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor. J Natl Compr Canc Netw 2013;11:1466–1470.
Frampton GM, Fichtenholtz A, Otto GA. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023–1031.
He J, Abdel-Wahab O, Nahas MK. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood 2016;127:3004–3014.
Klempner SJ, Bordoni R, Gowen K. Identification of BRAF kinase domain duplications across multiple tumor types and response to RAF-inhibitor therapy. JAMA Oncol 2016;2:272–274.
Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 2002;62:1573–1577.
Widemann BC, Reinke D, Helman L. SARC006: phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs) [abstract]. J Clin Oncol 2013;31(Suppl):Abstract 10522.
Hirbe AC, Pekmezci M, Dahiya S. BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Neuro Oncol 2014;16:466–467.
Schindler G, Capper D, Meyer J. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma, and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121:397–405.
Je EM, An CH, Yoo NJ, Lee SH. Mutational analysis of PIK3CA, JAK2, BRAF, FOXL2, IDH1, AKT1 and EZH2 oncogenes in sarcomas. APMIS 2012;120:635–639.
Bottillo I, Ahlquist T, Brekke H. Germline and somatic NF1 mutations in sporadic and NF-1 associated malignant nerve sheath tumors. J Pathol 2009;217:693–701.
Mackiewicz-Wysocka M, Krokowicz L, Kocur J, Mackiewicz J. Resistance to vemurafenib can be reversible after treatment interruption. Medicine (Baltimore) 2014;93:e157.
Schreuer M, Jansen Y, Planken S. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF V600-mutant melanoma: an open-label, single-arm, duel-centre, phase 2 clinical trial. Lancet Oncol 2017;18:464–472.
Jessen WJ, Miller S, Jousma E. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest 2013;123:340–347.
Chapman PB, Hauschild A, Robert C. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507–2516.
Flaherty KT, Jeffrey T, Infante JR. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694–1703.
Hutchinson KE, Lipson D, Stephens PJ. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res 2013;19:6696–6702.
Kulkarni A, Al-Hraishaw H, Simhadri S. BRAF fusion as a novel mechanism of acquired resistance to vemurafenib in BRAFV600E mutant melanoma. Clin Cancer Res 2017;23:5631–5638.
Chakraborty R, Burke TM, Hampton OA. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood 2016;128:2533–2537.
Diamond EL, Durham BH, Dogan A. Phase 2 trial of singe-agent cobimetinib for adults with BRAF V600-mutant and wild-type histiocytic disorders [abstract]. Blood 2017;130(Suppl 1):Abstract 257.
Yao Z, Torres NM, Tao A. BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. Cancer Cell 2015;28:370–383.
Nissan MH, Pratilas CA, Jones AM. Loss of NF 1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res 2014;74:2340–2350.
Krauthammer M, Kong Y, Bacchiocchi A. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet 2013;47:996–1002.
Whittaker SR, Theurillat JP, Van Allen E. Genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov 2013;13:350–362.
Dombi E, Baldwin A, Marcus LJ. Activity of selumetinib in neurofibromatosis type1-related plexiform neurofibromas. N Engl J Med 2016;375:2550–2560.
Morris EJ, Jha S, Restaino CR. Discovery of a novel ERK inhibitor with activity in models of acquired resistance of BRAF and MEK inhibitors. Cancer Discov 2013;3:742–750.
Sullivan RJ, Infante JP, Janku F. First-in-class ERK 1-2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study. Cancer Discov 2018;8:184–195.
Hyman DM, Puzanov I, Subbiah V. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015;373:726–736.
Yao YM, Donoho GP, Iversen PW. Mouse PDX trial suggests synergy of concurrent inhibition of RAF and EGFR in colorectal cancer with BRAF or KRAS mutations. Clin Cancer Res 2017;23:5547–5560.
Mistry M, Zhukova N, Merico D. BRAF mutation and CDKN2A/B deletion define a clinically distinct subgroup of childhood secondary high grade glioma. J Clin Oncol 2015;33:1015–1022.
Lassaletta A, Zapotocky M, Mistry M. Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol 2017;35:2934–2941.
Broniscer A. Malignant transformation of low-grade gliomas in children: lessons learned from rare medical events. J Clin Oncol 2015;33:978–979.
Schiffman JD, Hodgson JG, VandenBerg SR. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 2010;70:512–519.
Kumar R, Angelini S, Snellman E. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol 2004;122:342–348.
Sohier P, Luscan A, Lloyd A. Confirmation of mutation landscape of NF1 associated malignant peripheral nerve sheath tumor. Genes Chromosomes Cancer 2017;56:421–426.
Lee W, Teckie S, Wiesner T. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet 2014;46:1227–1232.
Isakoff SJ, Mahyer EL, Traina TA. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple negative breast cancer. J Clin Oncol 2015;33:1902–1909.
Massacesi C, DiTomaso E, Urba P. PI3K inhibitors as new cancer therapeutics: implications for clinical trial design. Onco Targets Ther 2016;9:203–210.
Levitski A. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu Rev Pharmacol Toxicol 2013;53:161–185.